Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Verastem, Inc. (VSTM)

Compare

5.16

-0.54

(-9.47%)

At close: April 4 at 4:00:01 PM EDT

5.14

-0.02

(-0.39%)

After hours: April 4 at 5:23:49 PM EDT

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 8 days ago

VSTM
-9.47%
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

BOSTON, March 25, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 to be held on April 25-30 in Chicago, Illinois. These presentations will highlight clinical and preclinical data from the Company’s development programs, including VS-7375 (GFH375), an oral KRAS G

Business Wire 10 days ago

VSTM
-9.47%
Verastem: Q4 Earnings Snapshot

NEEDHAM, Mass. AP) — Verastem Inc. VSTM) on Thursday reported a loss of $64.6 million in its fourth quarter.

Associated Press Finance 15 days ago

VSTM
-9.47%
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

BOSTON, March 20, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and highlighted recent progress.

Business Wire 15 days ago

VSTM
-9.47%
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

BOSTON, February 20, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster presentations, including an oral presentation of additional analyses from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) trial evaluating the investigational combination of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC), at the S

Business Wire last month

VSTM
-9.47%
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

BOSTON, January 29, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST.

Business Wire 2 months ago

VSTM
-9.47%
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

BOSTON, January 23, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for its novel clinical pipeline.

Business Wire 2 months ago

VSTM
-9.47%
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

BOSTON, January 15, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company’s executive leadership team.

Business Wire 2 months ago

VSTM
-9.47%
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

BOSTON, January 14, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor. In addition, the Company announced preliminary clinical data from the Phase 1 study being conducted by GenFleet in China.

Business Wire 2 months ago

VSTM
-9.47%
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

BOSTON, January 13, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced a new credit facility for up to $150 million along with an equity investment of $7.5 million with Oberland Capital Management LLC (Oberland Capital). In addition, the Company announced a strategic collaboration with IQVIA Inc. (IQVIA) to leverage IQVIA’s world-class infrastructure and established commercial

Business Wire 2 months ago

VSTM
-9.47%
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, January 08, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 15,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have

Business Wire 2 months ago

VSTM
-9.47%
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.

Zacks 2 months ago

VSTM
-9.47%
CTMX

CSTL
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

The treatment has been granted Priority Review, with a PDUFA action date of June 30, 2025.

GuruFocus.com 3 months ago

VSTM
-9.47%
Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell

US equity futures were cautiously higher ahead of Tuesday's opening bell as traders refrained from m

PREMIUM
MT Newswires 3 months ago

^FTSE

^GSPC

^DJI
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

BOSTON, December 30, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib, an oral FAK inhibitor, for the treatment of adult patients with recurrent low-grade serous ovarian cancer (LGSOC), w

Business Wire 3 months ago

VSTM
-9.47%
Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr

GlobeNewswire 3 months ago

RVPH

RVPHW

VSTM
-9.47%
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

BOSTON, December 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data for the triplet combination of avutometinib and sotorasib plus defactinib in the RAMP 203 Phase 1/2 study in KRAS G12C mutant advanced non-small cell lung cancer (NSCLC). No dose-limiting toxicities (DLTs) have been observed in the triplet combination. RAMP 203 continues to progress, with additional enrol

Business Wire 3 months ago

VSTM
-9.47%
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

BOSTON, November 26, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3rd at 11:15 am EST.

Business Wire 4 months ago

VSTM
-9.47%
Verastem: Q3 Earnings Snapshot

NEEDHAM, Mass. AP) — Verastem Inc. VSTM) on Wednesday reported a loss of $24 million in its third quarter.

Associated Press Finance 4 months ago

VSTM
-9.47%
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

BOSTON, November 06, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the third quarter ended September 30, 2024.

Business Wire 4 months ago

VSTM
-9.47%

Performance Overview

Return	VSTM	S&P 500 (^GSPC)
YTD	-0.19%	-13.73%
1-Year	-54.46%	-1.42%
3-Year	-71.90%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Verastem, Inc. (VSTM)

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Verastem: Q4 Earnings Snapshot

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Verastem: Q3 Earnings Snapshot

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Performance Overview